The percentages of EMAP+CD5+ and EMAP II+CD7+ cells were higher in new T-NHL patients than in healthy controls (median = 2.9% vs. 0.2%; 3.5% vs. 0.3%; P < 0.001). Here, CD7 is linked to non-Hodgkin lymphoma.